The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Melnikov M.V.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency;
Pirogov Russian National Research Medical University;
National Research Center Institute of Immunology of the Federal Medical Biological Agency

Lopatina A.V.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Sviridova A.A.

Federal Center of Brain research and Neurotechnologies of the Federal Medical Biological Agency of Russia

Pashenkov M.V.

National Research Center Institute of Immunology of the Federal Medical Biological Agency of Russia

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

The influence of fluoxetine on neuroimmune interaction in multiple sclerosis

Authors:

Melnikov M.V., Lopatina A.V., Sviridova A.A., Pashenkov M.V., Boyko A.N.

More about the authors

Read: 2940 times


To cite this article:

Melnikov MV, Lopatina AV, Sviridova AA, Pashenkov MV, Boyko AN. The influence of fluoxetine on neuroimmune interaction in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7‑2):65‑71. (In Russ.)
https://doi.org/10.17116/jnevro202312307265

Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
Resu­lts of 4 years of therapy with divo­zilimab in patients with rela­psing multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):51-59
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

References:

  1. Dobson R, Giovannoni G. Multiple sclerosis — a review. Eur J Neurol. 2019;26(1):27-40.  https://doi.org/10.1111/ene.13819
  2. Lassmann H. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front Immunol. 2019;9:3116. https://doi.org/10.3389/fimmu.2018.03116
  3. Nally FK, De Santi C, McCoy CE. Nanomodulation of Macrophages in Multiple Sclerosis. Cells. 2019;8(6):543.  https://doi.org/10.3390/cells8060543
  4. Goldmann T, Prinz M. Role of microglia in CNS autoimmunity. Clin Dev Immunol. 2013;2013:208093. https://doi.org/10.1155/2013/208093
  5. Kuhlmann T, Ludwin S, Prat A, et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2017;133(1):13-24.  https://doi.org/10.1007/s00401-016-1653-y
  6. Correale J, Halfon MJ, Jack D, et al. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103264. https://doi.org/10.1016/j.msard.2021.103264
  7. Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: A brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Mult Scler Relat Disord. 2017;18:177-180.  https://doi.org/10.1016/j.msard.2017.10.004
  8. Stamoula E, Siafis S, Dardalas I, et al. Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models. Front Immunol. 2021;12:677879. https://doi.org/10.3389/fimmu.2021.677879
  9. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.  https://doi.org/10.1016/S1474-4422(17)30470-2
  10. Kurtzke JF. Rating neurologyc impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
  11. Jeurink PV, Vissers YM, Rappard B, et al. T cell responses in fresh and cryopreserved peripheral blood mononuclear cells: kinetics of cell viability, cellular subsets, proliferation, and cytokine production. Cryobiology. 2008;57(2):91-103.  https://doi.org/10.1016/j.cryobiol.2008.06.002
  12. Gobin V, De Bock M, Broeckx BJ, et al. Fluoxetine suppresses calcium signaling in human T lymphocytes through depletion of intracellular calcium stores. Cell Calcium. 2015;58(3):254-263.  https://doi.org/10.1016/j.ceca.2015.06.003
  13. Pashenkov MV, Balyasova LS, Dagil YA, et al. The Role of the p38-MNK-eIF4E Signaling Axis in TNF Production Downstream of the NOD1 Receptor. J Immunol. 2017;198(4):1638-1648. https://doi.org/10.4049/jimmunol.1600467
  14. Han TH, Jin P, Ren J, et al. Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother. 2009;32(4):399-407.  https://doi.org/10.1097/CJI.0b013e31819e1773
  15. Billingham LK, Stoolman JS, Vasan K, et al. Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. Nat Immunol. 2022;23(5):692-704.  https://doi.org/10.1038/s41590-022-01185-3
  16. Du RH, Tan J, Sun XY, et al. Fluoxetine Inhibits NLRP3 Inflammasome Activation: Implication in Depression. Int J Neuropsychopharmacol. 2016;19(9):pyw037. https://doi.org/10.1093/ijnp/pyw037
  17. Wang C, Zhou Y, Feinstein A. Neuro-immune crosstalk in depressive symptoms of multiple sclerosis. Neurobiol Dis. 2023;177:106005. https://doi.org/10.1016/j.nbd.2023.106005
  18. Melnikov M, Lopatina A. Th17-cells in depression: Implication in multiple sclerosis. Front Immunol. 2022;13:1010304. https://doi.org/10.3389/fimmu.2022.1010304
  19. Koran LM, Cain JW, Dominguez RA, et al. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry. 1996;153(11):1450-1454. https://doi.org/10.1176/ajp.153.11.1450
  20. Kubera M, Lin AH, Kenis G, et al. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21(2):199-206.  https://doi.org/10.1097/00004714-200104000-00012
  21. Diamond M, Kelly JP, Connor TJ. Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006;16(7):481-490.  https://doi.org/10.1016/j.euroneuro.2005.11.011
  22. Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019;41(3):283-297.  https://doi.org/10.1007/s00281-019-00733-8
  23. Jiao L, Guo S. Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Front Immunol. 2022;13:966766. https://doi.org/10.3389/fimmu.2022.966766
  24. Mendiola AS, Cardona AE. The IL-1β phenomena in neuroinflammatory diseases. J Neural Transm (Vienna). 2018;125(5):781-795.  https://doi.org/10.1007/s00702-017-1732-9
  25. Melnikov M, Sviridova A, Rogovskii V, et al. Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy. Mult Scler Relat Disord. 2021;51:102888. https://doi.org/10.1016/j.msard.2021.102888
  26. Melnikov M, Kasatkin D, Lopatina A, et al. Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy. Front Neurol. 2022;13:920408. https://doi.org/10.3389/fneur.2022.920408

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.